Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) was the recipient of a significant growth in short interest in August. As of August 14th, there was short interest totaling 227,041 shares, a growth of 48.9% from the July 30th total of 152,432 shares. Based on an average daily trading volume, of 721,354 shares, the short-interest ratio is presently 0.3 days. Currently, 0.4% of the company’s stock are sold short.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Leerink Partners raised Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 target price on the stock in a research report on Tuesday, August 11th. BTIG Research increased their price target on Innate Pharma from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Weiss Ratings upgraded Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 26th. UBS Group reaffirmed a “buy” rating on shares of Innate Pharma in a report on Tuesday, August 11th. Finally, Citigroup upgraded shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research note on Tuesday, August 11th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $6.67.

Institutional Investors Weigh In On Innate Pharma

Several large investors have recently modified their holdings of the stock. Millennium Management LLC bought a new stake in shares of Innate Pharma in the 4th quarter worth approximately $36,000. OLD Mission Capital LLC purchased a new position in Innate Pharma in the fourth quarter valued at approximately $50,000. Finally, Jane Street Group LLC bought a new position in Innate Pharma during the fourth quarter valued at $162,000. Hedge funds and other institutional investors own 0.16% of the company’s stock.

Innate Pharma Stock Performance

NASDAQ IPHA traded down $0.05 during trading hours on Tuesday, reaching $2.12. 4,968 shares of the company were exchanged, compared to its average volume of 86,989. Innate Pharma has a 1 year low of $1.17 and a 1 year high of $2.71. The business’s 50 day simple moving average is $1.93 and its 200-day simple moving average is $1.72.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.